BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30338612)

  • 1. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.
    Betti M; Aspesi A; Ferrante D; Sculco M; Righi L; Mirabelli D; Napoli F; Rondón-Lagos M; Casalone E; Vignolo Lutati F; Ogliara P; Bironzo P; Gironi CL; Savoia P; Maffè A; Ungari S; Grosso F; Libener R; Boldorini R; Valiante M; Pasini B; Matullo G; Scagliotti G; Magnani C; Dianzani I
    Genes Chromosomes Cancer; 2018 Nov; 57(11):573-583. PubMed ID: 30338612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.
    Lalloo F; Kulkarni A; Chau C; Nielsen M; Sheaff M; Steele J; van Doorn R; Wadt K; Hamill M; Torr B; Tischkowitz M; ; Hanson H
    Eur J Hum Genet; 2023 Nov; 31(11):1261-1269. PubMed ID: 37607989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1-associated protein 1: Tumor predisposition syndrome and Kury-Isidor syndrome, from genotype-phenotype correlation to clinical management.
    West EC; Chiappetta M; Mattingly AA; Congedo MT; Evangelista J; Campanella A; Sassorossi C; Flamini S; Rossi T; Pistoni M; Abenavoli L; Margaritora S; Lococo F; Boccuto L
    Clin Genet; 2024 Jun; 105(6):589-595. PubMed ID: 38506155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma.
    Carbone M; Minaai M; Takinishi Y; Pagano I; Yang H
    J Transl Med; 2023 Oct; 21(1):749. PubMed ID: 37880686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex Genomic Rearrangement Patterns in Malignant Pleural Mesothelioma due to Environmental Asbestos Exposure.
    Tuncel T; Ak G; Güneş HV; Metintaş M
    J Environ Pathol Toxicol Oncol; 2024; 43(2):13-27. PubMed ID: 38505910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
    Sato H; Ito T; Hayashi T; Kitano S; Erdjument-Bromage H; Bott MJ; Toyooka S; Zauderer M; Ladanyi M
    Oncogene; 2024 Apr; 43(15):1087-1097. PubMed ID: 38383726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma.
    Amelio I
    Cell Death Dis; 2017 Jun; 8(6):e2907. PubMed ID: 28661472
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome.
    Lebensohn A; Ghafoor A; Bloomquist L; Royer MC; Castelo-Soccio L; Karacki K; Hathaway O; Maglo T; Wagner C; Agra MG; Blakely AM; Schrump DS; Hassan R; Cowen EW
    JAMA Dermatol; 2024 May; ():. PubMed ID: 38759225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma.
    Xu D; Gao Y; Yang H; Spils M; Marti TM; Losmanová T; Su M; Wang W; Zhou Q; Dorn P; Shu Y; Peng RW
    JTO Clin Res Rep; 2024 May; 5(5):100672. PubMed ID: 38715965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.
    Rossi G; Righi L; Barbisan F; Tiseo M; Spagnolo P; Grosso F; Pisapia P; Malapelle U; Sculco M; Dianzani I; Abate-Daga L; Davolio MC; Ceresoli GL; Galetta D; Pasello G; Novello S; Bironzo P
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.
    Mukherjee S; Bandlamudi C; Hellmann MD; Kemel Y; Drill E; Rizvi H; Tkachuk K; Khurram A; Walsh MF; Zauderer MG; Mandelker D; Topka S; Zehir A; Srinivasan P; Esai Selvan M; Carlo MI; Cadoo KA; Latham A; Hamilton JG; Liu YL; Lipkin SM; Belhadj S; Bond GL; Gümüş ZH; Klein RJ; Ladanyi M; Solit DB; Robson ME; Jones DR; Kris MG; Vijai J; Stadler ZK; Amos CI; Taylor BS; Berger MF; Rudin CM; Offit K
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1450-1459. PubMed ID: 35477182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline cancer predisposition variants and pediatric glioma: a population-based study in California.
    Muskens IS; de Smith AJ; Zhang C; Hansen HM; Morimoto L; Metayer C; Ma X; Walsh KM; Wiemels JL
    Neuro Oncol; 2020 Jun; 22(6):864-874. PubMed ID: 31970404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline cancer susceptibility in individuals with melanoma.
    Funchain P; Ni Y; Heald B; Bungo B; Arbesman M; Behera TR; McCormick S; Song JM; Kennedy LB; Nielsen SM; Esplin ED; Nizialek E; Ko J; Diaz-Montero CM; Gastman B; Stratigos AJ; Artomov M; Tsao H; Arbesman J
    J Am Acad Dermatol; 2024 Mar; ():. PubMed ID: 38513832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline variants of DNA repair and immune genes in lymphoma from lymphoma-cancer families.
    Wang X; Deng L; Ping L; Shi Y; Wang H; Feng F; Leng X; Tang Y; Xie Y; Ying Z; Liu W; Zhu J; Song Y
    Int J Cancer; 2024 Jul; 155(1):93-103. PubMed ID: 38446987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterisation guides classification of novel
    Hong JH; Chong ST; Lee PH; Tan J; Heng HL; Ishak NDB; Chan SH; Teh BT; Ngeow J
    NPJ Genom Med; 2020; 5():50. PubMed ID: 33240524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment.
    Febres-Aldana CA; Fanaroff R; Offin M; Zauderer MG; Sauter JL; Yang SR; Ladanyi M
    Annu Rev Pathol; 2024 Jan; 19():11-42. PubMed ID: 37722697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.
    Hubert JN; Suybeng V; Vallée M; Delhomme TM; Maubec E; Boland A; Bacq D; Deleuze JF; Jouenne F; Brennan P; McKay JD; Avril MF; Bressac-de Paillerets B; Chanudet E
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34067022
    [No Abstract]   [Full Text] [Related]  

  • 18. Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.
    Yang H; Xu D; Yang Z; Yao F; Zhao H; Schmid RA; Peng RW
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824422
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma.
    Landman N; Hulsman D; Badhai J; Kopparam J; Puppe J; Pandey GK; van Lohuizen M
    Br J Cancer; 2024 Mar; ():. PubMed ID: 38519707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.
    Song Y; Baxter SS; Dai L; Sanders C; Burkett S; Baugher RN; Mellott SD; Young TB; Lawhorn HE; Difilippantonio S; Karim B; Kadariya Y; Pinto LA; Testa JR; Shoemaker RH
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.